aTyr Pharma
ATYR
23 hedge funds and large institutions have $22.9M invested in aTyr Pharma in 2020 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 7 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
23% more capital invested
Capital invested by funds: $18.5M → $22.9M (+$4.32M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.16% less ownership
Funds ownership: 58% → 57.84% (-0.16%)
8% less funds holding
Funds holding: 25 → 23 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.46M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$457K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$329K |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$152K |
| 5 |
VF
Virtu Financial
New York
|
+$101K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$1.9M |
| 2 |
Two Sigma Investments
New York
|
-$386K |
| 3 |
Renaissance Technologies
New York
|
-$326K |
| 4 |
Two Sigma Advisers
New York
|
-$305K |
| 5 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$65K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| – | -$4K | -1,311 | Closed |
|
27
Wells Fargo
San Francisco,
California
| – | +$26 | +7 | +13% |
|
ATYR Hedge Fund Activity: Q4 2020 in Review
23 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q4 2020, worth a combined $22.9M — up 23% from $18.5M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ATYR and 5 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 7 added.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $1.46M. The largest seller was Viking Global Investors, exiting entirely with an estimated $1.9M sold.
- 23 institutional investors held aTyr Pharma (ATYR) as of Q4 2020, down from 25 in Q3 2020.
- Funds reported $22.9M of aTyr Pharma stock for Q4 2020, up 23% quarter-over-quarter.
- 5 funds opened new aTyr Pharma positions in Q4 2020 and 7 closed out, a net change of -2 holders.
- The largest aTyr Pharma buyer in Q4 2020 was Ikarian Capital, an estimated $1.46M added.
- The largest aTyr Pharma seller in Q4 2020 was Viking Global Investors, an estimated $1.9M sold.
Based on aggregated 13F filings for Q4 2020.